Table 1.
Baseline Characteristics
| All patients (N=13) | |
|---|---|
| Age at time of analysis (years) -Median (Range) | 72 (37-81) |
| Age at Diagnosis (years) -Median (Range) | 61 (30-77) |
| Duration from RAI-refractory disease up to the beginning of a therapy in (months) - Median (Range) | 48 (2-96) |
| Sites of Metastasis Median Number (Range) | 1 (0-4) |
| Lung | 12 |
| Bone | 9 |
| Lymph nodes | 4 |
| Soft tissue | 2 |
| Liver | 2 |
| Brain | 2 |
| Heart | 1 |
| Previous systemic treatment before Lenvatinib Median Number (Range) | 1 (0-4) |
| Sorafenib | 8 |
| Pazopanib | 1 |
| Vandetanib | 1 |
| Chemotherapy (Cisplatin/Doxorubicin or TCF) | 2 |
| None | 4 |